Live — Batch 01 Active
500 Units — Founding Members Only

COVERT

AXIS SystemPDRN-01Patent Pending

Control the signal

Measured treatment. Controlled delivery.

Founding batch. 500 units.

The Problem

Most skin treatment operates open-loop.

No measurement before delivery. No metering during. No confirmation after. Topical compounds meet the stratum corneum and lose the majority of their active payload before reaching target depth.

That is not treatment. That is application.

COVERT closes the loop.

The Protocol

Three components. One closed-loop system.

SignalA dedicated scan interface, used once per week. Reads hydration, barrier state, inflammation, and temperature. Skin mapped over time. The protocol is derived from accumulated signal, not assumption.
AxisHandheld precision treatment device. Thermal conditioning prepares the dermal layer. Metered delivery ensures the active reaches target depth.
PayloadSealed compound cartridge. PDRN. Metered sessions. No air exposure. No contamination. No guessing.

The Compound

The challenge was never efficacy. It was delivery.

PDRN — Polydeoxyribonucleotide. A compound derived from salmon DNA, documented in tissue regeneration and cellular repair research.

The delivery problem is physics. PDRN molecules exceed the skin's passive penetration threshold. Without active delivery, the compound stays on the surface.

AXIS was built to cross that barrier.

PDRN — peer-reviewed research since 1994 / tissue regeneration / wound healing / dermal restoration

Founding

500 units. No second allocation.

Batch 01 is not a limited edition. It is a production constraint. Access is extended, not applied for.

No public launch. No exceptions.

Limited release / Patent Pending / Founding list